Eli Lilly and Company (NYSE: LLY) announced results from the VIVID-2 open-label extension study, which showed the majority of patients with moderately to severely active Crohn's disease receiving two ...

The Business Research Company's Comprehensive Insights Of The Global Omvoh Market: Key Drivers, Trends, Growth Opportunities, And Forecast For 2025-2034 It will grow ...

The U.S. Food and Drug Administration has approved Eli Lilly's Omvoh (mirikizumab-mrkz) for the treatment of moderately to severely active Crohn's disease in adults. Crohn's disease, also known as ...

The Phase I trial is currently underway in Australia, with plans to extend into the US and China. Credit: Volha_R/Shutterstock. CStone Pharmaceuticals has dosed the first subject in the multicentre ...

Uranium markets have not been insulated from the swathe of uncertainty eminating from the White House, impacting both actvity and pricing. The proposed Trump tariffs on Canada, Mexico, and China are ...

Italy plans to utilise advanced modular reactors to produce sustainable nuclear energy while also decarbonising its most polluting industries. Credit: barmalini/Shutterstock. The Italian government ...

The European Commission will review the CHMP recommendation to determine issuing an expanded Marketing Authorisation, and a decision is expected in due course. 2 J&J Data on file (RF-452642). European ...

These new medicines include Alzheimer's disease treatment Kisunla, ulcerative colitis medication Omvoh, and cancer drug Jaypirca. Of course, Lilly's most important new products are diabetes ...